Evidence map›Paper›PMID 29684633›Full record

Trial reportClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2019

Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial.

S Magnan, J E Tota, M El-Zein, A N Burchell, J T Schiller, A Ferenczy, P-P Tellier, F Coutlée, E L Franco, CATCH Study Group

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Human Papillomavirus (HPV) Entry Inhibitors.Advances in experimental medicine and biology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

S MagnanDivision of Cancer Epidemiology, McGill University, Montreal, QC, Canada.
J E TotaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
M El-ZeinDivision of Cancer Epidemiology, McGill University, Montreal, QC, Canada.
A N BurchellDepartment of Family and Community Medicine and Center for Urban Health Solutions, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada.
J T SchillerDepartment of Health and Human Services, National Cancer Institute, Bethesda, MD, USA.
A FerenczyDepartment of Pathology, McGill University, Montreal, QC, Canada.
P-P TellierDepartment of Family Medicine, McGill University, Montreal, QC, Canada.
F CoutléeDépartement de Microbiologie et infectiologie, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
E L FrancoDivision of Cancer Epidemiology, McGill University, Montreal, QC, Canada. Electronic address: eduardo.franco@mcgill.ca.
CATCH Study Group
McGill University · CANational Cancer Institute · USCentre Hospitalier de l’Université de Montréal · CAMcGill University Health Centre · CASt. Michael's Hospital · CA

Funding

Understanding Papillomavirus Virion Proteins and VaccinesZIABC009052 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHILLER, JOHN T. · 2009 to 2025
$38.4M
Intramural NIH HHS ZIA BC009052
6 · The paper itself

Abstract

objectivesTo evaluate the efficacy of a carrageenan-based lubricant gel in reducing the risk of genital human papillomavirus (HPV) infections in women.

methodsWe conducted a planned interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. Women aged 18 years and older were randomly assigned (1:1) to a carrageenan-based gel or a placebo gel to be self-applied every other day for the first month and before and after each intercourse during follow-up. Assessments were performed at 0.5, 1, 3, 6, 9 and 12 months. The primary outcome was incidence of a new infection by an HPV type that was not present at baseline. Intention-to-treat analyses were performed.

resultsBetween January 2013 and June 2017, a total of 280 participants were randomly assigned to the carrageenan (n = 141) or the placebo (n = 139) arm. All participants were included in safety analyses, but three (1%) were excluded from efficacy analyses (HPV results unavailable for two participants in the carrageenan and one participant in the placebo arm). The median follow-up time was 9.2 months (interquartile range, 1.9-13.2 months). A total of 59 (42%) of 139 participants in the carrageenan arm and 78 (57%) of 138 participants in the placebo arm became infected by at least one new HPV type (hazard ratio = 0.64, 95% confidence interval = 0.45-0.89, p 0.009). A total of 62 (44%) of 141 participants in the carrageenan arm versus 43 (31%) of 139 participants in the placebo arm reported an adverse event (p 0.02), none of which was deemed related to the gels.

conclusionsOur trial's interim analysis suggests that using a carrageenan-based lubricant gel can reduce the risk of genital HPV infections in women.

Indexed as

CarrageenanGelsPapillomaviridaeAdministration, IntravaginalAdultDouble-Blind MethodFemaleHumansPapillomavirus InfectionsUterine Cervical DiseasesCarrageenanGelsCarrageenanGelHPVHuman papillomavirusMicrobicideRandomized controlled trial

Identifiers

PMID29684633
PMCPMC8274946
OpenAlexW2802953052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.